Medication info
Gemimet Extended-Release Tablet 25/1000 mg

Gemimet Extended-Release Tablet 25/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Gemigliptin Tartrate Sesquihydrate›34.45mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
LG Chem, Ltd.
Appearance
Yellowish-brown oblong film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle, 56 tablets (14 tablets/PTP×4)
Approval status
Active

MFDS item code 201604114 · Approved 2016.06.30 · Insurance code 668903060

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability. This drug is generally administered with the evening meal, with gradual dose escalation to reduce gastrointestinal adverse reactions associated with metformin. Take 1 tablet of this drug 50/500mg extended-release tablets or 50/1000mg extended-release tablets once daily. Patients taking this drug 25/500mg extended-release tablets or 25/1000mg extended-release tablets should take 2 tablets together once daily. - For patients who are not currently receiving metformin treatment and require gemigliptin 50mg, the recommended starting dose of this drug is one gemigliptin 50mg/metformin 500mg extended-release tablet once daily, with gradual dose escalation to reduce gastrointestinal adverse reactions associated with metformin. - For patients whose blood glucose is not adequately controlled with metformin monotherapy, combination therapy with metformin and a sulfonylurea, or combination therapy with metformin and insulin, the initial dose of this drug should provide gemigliptin 50 mg once daily and the patient's existing metformin dose. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and dose adjustment made as appropriate. - When this drug is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be necessary to reduce the risk of hypoglycemia. - For patients switching to this drug from combination therapy with gemigliptin and metformin, the dose of this drug may be started at the existing doses of gemigliptin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and dose adjustment made as appropriate. The maximum recommended daily dose is gemigliptin 50mg and extended-release metformin 2000mg. The safety and efficacy of this drug have not been specifically evaluated in patients switching to it from other antihyperglycemic agents. Since any change may cause a change in blood glucose control, any change in treatment for patients with type 2 diabetes should be made under careful monitoring. Swallow this drug whole; do not crush, cut, or chew it.

Ingredients

Manufacturer
LG Chem, Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication effectively aids patients with type 2 diabetes in controlling their blood sugar when used alongside diet and exercise. The combination of gemigliptin and metformin stabilizes blood sugar levels and is very helpful in diabetes management. Therefore, this medication is used to improve blood sugar control.

How to take

Adult dose

The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability. This drug is generally administered with the evening meal, with gradual dose escalation to reduce gastrointestinal adverse reactions associated with metformin. Take 1 tablet of this drug 50/500mg extended-release tablets or 50/1000mg extended-release tablets once daily. Patients taking this drug 25/500mg extended-release tablets or 25/1000mg extended-release tablets should take 2 tablets together once daily. - For patients who are not currently receiving metformin treatment and require gemigliptin 50mg, the recommended starting dose of this drug is one gemigliptin 50mg/metformin 500mg extended-release tablet once daily, with gradual dose escalation to reduce gastrointestinal adverse reactions associated with metformin. - For patients whose blood glucose is not adequately controlled with metformin monotherapy, combination therapy with metformin and a sulfonylurea, or combination therapy with metformin and insulin, the initial dose of this drug should provide gemigliptin 50 mg once daily and the patient's existing metformin dose. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and dose adjustment made as appropriate. - When this drug is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be necessary to reduce the risk of hypoglycemia. - For patients switching to this drug from combination therapy with gemigliptin and metformin, the dose of this drug may be started at the existing doses of gemigliptin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and dose adjustment made as appropriate. The maximum recommended daily dose is gemigliptin 50mg and extended-release metformin 2000mg. The safety and efficacy of this drug have not been specifically evaluated in patients switching to it from other antihyperglycemic agents. Since any change may cause a change in blood glucose control, any change in treatment for patients with type 2 diabetes should be made under careful monitoring. Swallow this drug whole; do not crush, cut, or chew it.

Precautions

This medication is an antidiabetic agent that helps control blood sugar. However, a serious side effect called lactic acidosis, which occurs when excessive lactic acid builds up in the body, can occur very rarely. This may pose a life-threatening risk, so immediate medical attention is necessary if symptoms occur. Caution is advised when taking this medication in conjunction with insulin or other antidiabetic medications, as severe hypoglycemia may occur. Patients who have had allergic reactions to this medication or similar medications, those with serious kidney impairment, severe heart function decline, or those with acute heart disease or sepsis should not take this medication. If you are scheduled to receive iodine contrast agents used in radiation tests, you should discontinue this medication 48 hours prior to the test and only resume it after confirming normal kidney function. It is recommended that pregnant or breastfeeding women avoid taking this medication. In cases of suspected acute pancreatitis, this medication should be discontinued immediately, and caution is advised for those with a history of pancreatitis. This medication may lower vitamin B12 levels with long-term use, so yearly blood tests are recommended for monitoring. If sudden severe abdominal pain, muscle pain, shortness of breath, or weakness occurs while taking this medication, immediate consultation with a healthcare provider is necessary. Additionally, this medication may cause allergic reactions, skin rashes, hives, and joint pain in some patients, so any abnormal symptoms should be discussed with a doctor. Elderly patients or those with decreased kidney function should be especially cautious during use and should undergo regular kidney function tests. In case of overdose, immediate medical attention should be sought, and blood dialysis may be necessary to remove the drug if needed. Lastly, note that some components of this medication may be expelled unchanged in the stool, so there is no need for concern. However, if frequently observed, inform your healthcare provider.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • arthralgia
  • rhinitis
  • bacteriuria
  • upper respiratory tract infection
  • increased serum CPK levels
  • fever
  • diarrhea
  • urinary tract infection
Show 48 more
  • dizziness
  • nausea
  • weakness
  • myalgia
  • headache
  • constipation
  • hypoglycemia accompanied by symptoms
  • hypersensitivity reaction
  • acute pancreatitis
  • bullous pemphigoid
  • rash
  • urticaria
  • gastritis
  • gastroesophageal reflux
  • unspecified gastrointestinal disorders
  • gastroenteritis
  • dyspnea
  • bronchitis
  • sinusitis
  • chest pain
  • leg edema
  • arthritis
  • conjunctivitis
  • iron deficiency anemia
  • onychomycosis
  • abdominal pain
  • cough
  • increased ALT
  • increased AST
  • motion sickness
  • glaucoma
  • allergic conjunctivitis
  • loss of appetite
  • anemia
  • angina
  • palpitations
  • arrhythmia
  • worsening of hypertension
  • increase in blood pressure
  • insomnia
  • soft tissue infection
  • intracranial hemorrhage
  • contusion
  • thyroiditis
  • leukocytosis
  • benign prostatic hyperplasia
  • irregular menstruation
  • laceration

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It's important to maintain a storage temperature of between 1 and 30 degrees Celsius to preserve the medication’s effectiveness.

Appearance and packaging

Appearance

Yellowish-brown oblong film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle, 56 tablets (14 tablets/PTP×4)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.